Intervention Review

Lisuride for levodopa-induced complications in Parkinson's disease

  1. C E Clarke1,*,
  2. Julie Speller2

Editorial Group: Cochrane Movement Disorders Group

Published Online: 25 JAN 1999

Assessed as up-to-date: 24 NOV 1998

DOI: 10.1002/14651858.CD001515

How to Cite

Clarke CE, Speller J. Lisuride for levodopa-induced complications in Parkinson's disease. Cochrane Database of Systematic Reviews 1999, Issue 1. Art. No.: CD001515. DOI: 10.1002/14651858.CD001515.

Author Information

  1. 1

    City Hospital NHS Trust, Department of Neurology, Birmingham, West Midlands, UK

  2. 2


*C E Clarke, Department of Neurology, City Hospital NHS Trust, Dudley Road, Birmingham, West Midlands, B18 7QH, UK.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 25 JAN 1999




  1. Top of page
  2. Abstract
  3. 摘要


Long-term levodopa therapy in Parkinson's disease is associated with the development of motor complications including abnormal involuntary movements and a shortening response to each dose (wearing off phenomenon). It is thought that dopamine agonists can reduce the duration of immobile off periods and the need for levodopa therapy whilst maintaining or improving motor impairments and only minimally increasing dopaminergic adverse events.


To compare the efficacy and safety of adjuvant lisuride therapy versus placebo in patients with Parkinson's disease, already established on levodopa and suffering from motor complications.

Search methods

Electronic searches of MEDLINE, EMBASE and the Cochrane Controlled Trials Register. Handsearching of the neurology literature as part of the Cochrane Movement Disorders Group's strategy. Examination of the reference lists of identified studies and other reviews. Contact with Cambridge Laboratories and Roche Products Limited.

Selection criteria

Randomised controlled trials of lisuride versus placebo in patients with a clinical diagnosis of idiopathic Parkinson's disease and long-term complications of levodopa therapy.

Data collection and analysis

Data was to be abstracted independently by each author and differences settled by discussion.

Main results

No randomised controlled trials comparing lisuride with placebo in advanced Parkinson's disease with motor complications were found.

Authors' conclusions

Well designed randomised controlled trials demonstrating efficacy and safety are required before the use of lisuride in later Parkinson's disease can be supported.



  1. Top of page
  2. Abstract
  3. 摘要



對巴金森氏症採取長期使用的左多巴療法可能會導致運動相關的併發症, 包括不正常的非自主運動與每次投藥有效時間縮短等(消逝現象). 多巴胺促進劑可以減少病患無法活動的時間, 和在維持或改善運動功能的前提下, 減少患者對左多巴的需要, 且只會輕微的增加多巴胺性的副作用.


針對已在使用左多巴胺且深受長期使用下之副作用的巴金森氏症病人, 對於添加lisurie或安慰劑,比較其療效與安全性.


電子搜尋MEDLINE, EMBASE and the Cochrane Controlled Trials Register.手動搜尋Cochrane Movement Disorders Group's strategy內的神經學文獻, 並檢視確立出來的研究及回顧的參閱書目,與Cambridge Laboratories 以及 Roche Products Limited聯絡.


以符合巴金森氏症之臨床診斷且身受長期左多巴胺治療之併發症之病人為對象, 針對lisuride與安慰劑之間作比較的隨機對照試驗









此翻譯計畫由臺灣國家衛生研究院(National Health Research Institutes, Taiwan)統籌。


無 無